In MS patients, greater numbers of peripheral CD4+ T cells are found that express higher surface levels of PSGL-1 than in controls, suggesting an enhanced capacity to interact with CNS ECs in a PSGL-1 dependent manner[6, 9]. The gene discussed is CD4; the disease is myeloid sarcoma.